SML0131
ABT-751 hydrochloride
≥98% (HPLC)
别名:
N-[2-[(4-Hydroxyphenyl)amino]-3-pyridyl]-4-methoxybenzenesulfonamide hydrochloride
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H17N3O4S · HCl
化学文摘社编号:
分子量:
407.87
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Quality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
pink to purple
solubility
DMSO: ≥15 mg/mL
originator
Abbott
storage temp.
2-8°C
SMILES string
Cl.COc1ccc(cc1)S(=O)(=O)Nc2cccnc2Nc3ccc(O)cc3
InChI
1S/C18H17N3O4S.ClH/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13;/h2-12,21-22H,1H3,(H,19,20);1H
InChI key
KWQWWUXRGIIBAS-UHFFFAOYSA-N
Biochem/physiol Actions
ABT-751 is an orally bioavailable vascular disrupting agent (VDA) with a broad spectrum of antitumor activity. It binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules.
ABT-751, a sulfonamide antimitotic agent, is under clinical trials to treat patients with various malignancies including refractory hematologic malignancies, non-small cell lung cancer (NSCLC), and colon cancer.
Orally bioavailable vascular disrupting agent (VDA) that binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules; broad spectrum of antitumor activity.
Features and Benefits
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0131-25MG | 04061833027202 |
| SML0131-5MG | 04061833027219 |